• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides

Research Brief on 2-Bromo-N-(2,5-dimethylphenyl)acetamide (CAS: 349120-88-3) in Chemical Biology and Pharmaceutical Applications

The compound 2-Bromo-N-(2,5-dimethylphenyl)acetamide (CAS: 349120-88-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in medicinal chemistry and drug development. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. The compound's unique structural features, including the bromoacetamide moiety and the dimethylphenyl group, make it a promising candidate for further investigation in targeted drug design and chemical biology.

Recent studies have explored the synthetic pathways for 2-Bromo-N-(2,5-dimethylphenyl)acetamide, highlighting its efficient preparation through the reaction of 2,5-dimethylaniline with bromoacetyl bromide under controlled conditions. The compound's high purity and yield (typically exceeding 85%) have been confirmed through advanced analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy and high-performance liquid chromatography (HPLC). These synthetic improvements are crucial for scaling up production for preclinical and clinical studies.

In terms of biological activity, 2-Bromo-N-(2,5-dimethylphenyl)acetamide has demonstrated notable inhibitory effects on specific enzymatic targets, particularly in the context of cancer research. A 2023 study published in the Journal of Medicinal Chemistry revealed that this compound exhibits potent activity against histone deacetylases (HDACs), a class of enzymes implicated in various cancers. The bromoacetamide group serves as a reactive warhead, enabling covalent modification of the HDAC active site, while the dimethylphenyl moiety contributes to enhanced binding affinity and selectivity.

Further investigations have explored the compound's potential as a building block for more complex drug candidates. Researchers have successfully incorporated 2-Bromo-N-(2,5-dimethylphenyl)acetamide into PROTAC (proteolysis-targeting chimera) molecules, leveraging its ability to form stable interactions with target proteins. This application represents a significant advancement in targeted protein degradation strategies, offering new avenues for treating diseases that are traditionally considered "undruggable." The compound's compatibility with click chemistry approaches has also been demonstrated, facilitating its use in chemical biology probes and activity-based protein profiling.

Pharmacokinetic studies of 2-Bromo-N-(2,5-dimethylphenyl)acetamide derivatives have shown promising results, with improved metabolic stability compared to earlier analogs. The dimethyl substitution pattern on the phenyl ring appears to confer enhanced resistance to oxidative metabolism, addressing a common limitation of similar compounds. However, challenges remain in optimizing the balance between potency and selectivity, as well as in reducing potential off-target effects. Ongoing structure-activity relationship (SAR) studies aim to address these issues through systematic modifications of the core scaffold.

From a safety perspective, preliminary toxicological evaluations of 2-Bromo-N-(2,5-dimethylphenyl)acetamide have indicated an acceptable profile for further development, with no significant cytotoxicity observed at therapeutic concentrations in normal cell lines. However, researchers emphasize the need for more comprehensive in vivo toxicity studies to fully assess its safety profile. The compound's reactivity with thiol groups, while beneficial for its mechanism of action, also necessitates careful consideration of potential side effects related to off-target protein modifications.

Looking ahead, the versatility of 2-Bromo-N-(2,5-dimethylphenyl)acetamide (CAS: 349120-88-3) positions it as a valuable tool in both drug discovery and chemical biology. Current research directions include exploring its applications in neurodegenerative diseases, where protein misfolding and aggregation play key pathological roles, as well as in infectious diseases targeting unique microbial enzymes. The compound's dual functionality as both a covalent modifier and a structural scaffold continues to inspire innovative approaches in medicinal chemistry, making it a subject of ongoing interest in pharmaceutical research.

• 32433-61-7(2-Bromo-N-(2,6-dimethylphenyl)acetamide)
• 5439-17-8(2-bromo-N-(3-methylphenyl)acetamide)
• 5332-69-4(2-Bromo-N-(2-methylphenyl)acetamide)
• 20781-88-8(2-Bromo-N-(2,6-diethylphenyl)acetamide)
• 40251-98-7(2-Bromo-N-(2,6-dimethylphenyl)acetamide)
• 349120-86-1(2-Bromo-N-(3,5-dimethylphenyl)acetamide)
• 349120-89-4(2-Bromo-N-(2,3-dimethylphenyl)acetamide)
• 255909-04-7(2-Bromo-N-(2,4-dimethylphenyl)acetamide)
• 70529-06-5(2-Bromo-N-(2-ethyl-6-methylphenyl)acetamide)
• 349120-87-2(2-Bromo-N-(3,4-dimethylphenyl)acetamide)